ClinicalTrials.gg
CompletedNCT02909400KHENERGYUpdated Feb 23, 2018

The KHENERGY Study

A Phase 2 interventional study of KH176 and placebo in Mitochondrial Diseases, Mitochondrial Myopathies and Mitochondrial Encephalomyopathies, sponsored by Khondrion BV. Completed at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-02-23.

Primary conditionMELAS SyndromeRegistry: Mitochondrial DiseasesReclassifiedWhy we changed it
Registry
Mitochondrial Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
MELAS Syndrome
Why
  1. The study's listed conditions name MELAS Syndrome, a narrower term within Mitochondrial Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Khondrion BV · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Mitochondrial Diseases are rare, progressive, multi-system, often-early fatal disorders affecting both children and adults. KH176 is a novel chemical entity currently under development for the treatment of inherited mitochondrial diseases, including MELAS (Mitochondrial Encephalomyopathy, Lactic acidosis, and Stroke-like episodes), MIDD (Maternally Inherited Diabetes and Deafness), Leigh's Disease and LHON (Leber's Hereditary Optic Neuropathy). The current Proof of Concept study aims to explore the effects of treatment with KH176 for 4 weeks on clinical signs and symptoms and biomarkers of mitochondrial disease and to evaluate the safety and pharmacokinetics of KH176 in patients with m.3242A>G related mitochondrial disease.

Read the detailed description

The trial will be a double blind, randomized, placebo-controlled, single-centre, two-way cross-over trial. Twenty patients, with a confirmed mitochondrial DNA tRNALeu(UUR) m.3243A>G mutation and with clinical signs of mitochondrial disease, will be randomized over 2 groups (active or placebo first). After a screening period and a training session, each group will have 2 dosing periods of 28 days, with a washout period of at least 28 days in between. On these occasions, patients will receive 100 mg KH176 twice daily (treatment A) or a matching placebo (treatment B) twice daily for 28 days.

Clinical assessments will be performed once in a training session prior to baseline, at baseline and in week 4 post dosing during each treatment phase (A and B). Testing conditions and circumstances, with respect to timing of the assessments, hospitalization and meals, will be standardized for each assessement period. Furthermore, assessments of biomarkers for mitochondrial functioning, pharmacokinetics and specific safety assessments will be performed weekly.

02

Conditions studied

  • Mitochondrial Diseases
  • Mitochondrial Myopathies
  • Mitochondrial Encephalomyopathies
  • MELAS
  • MIDD

Browse trials for

Keywords

  • mitochondrial
  • oxidative phosphorylation (oxphos)
  • MELAS
  • MIDD
  • KH176
  • Proof of Concept
03

In context

MELAS Syndrome Reclassified

37 studies on the registry are indexed under MELAS Syndrome; 8 are open to participants now.

This study's enrollment of 20 is below the median of 24 across 29 interventional studies indexed under MELAS Syndrome.

Browse MELAS Syndrome studies →

Lead sponsor

Khondrion BV is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Compared within MELAS Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Mitochondrial Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females aged 18 years or older at screening
  2. Ability and willingness to sign the Form prior to screening evaluations.
  3. Confirmed mitochondrial DNA tRNALeu(UUR) m.3243A>G mutation
  4. Heteroplasmy level as measured in urine ≥ 20 %.
  5. (BMI) 18.0-30.0 kg/m2 (extremes included) at screening
  6. Clinical evidence of mitochondrial disease, positive NMDAS score (including but not limited to MELAS, MIDD and mixed types). CPEO patients with signs restricted to the eye only are not considered eligible.
  7. Disease appropriate physical and mental health as established by medical history, physical examination, (ECG) and vital signs recording, and results of biochemistry, hematology and urinalysis testing within 3 weeks prior to the first dose as judged by the Investigator.
  8. Appropriate cardiac functioning as assessed by medical history, ECG and Echo, evaluated by a cardiologist.
  9. Able to comply with the study requirements, including exercise testing and swallowing study medication
  10. Willingness to use adequate methods (male and female) and negative urine pregnancy test (females) at screening and first baseline assessment.
  11. Able and willing to refrain from the use of (multi)vitamins, co-enzyme Q10, Vitamine E, riboflavin, and anti-oxidant supplements (and idebenone/EPI-743), as well as any medication negatively influencing mitochondrial functioning (including but not limited to valproic acid, glitazones, statins, anti-virals, amiodarone, and NSAID's) as well as any strong Cytochrome P450 inhibitors (all 'conazoles-anti-fungals', antivirals, grapefruit) and strong Cytochrome P450 inducers (a.o. carbamazepine, phenobarbital, phenytoin, rifampicine, St Johns wort, pioglitazone, troglitazone) as well as any medication known to affect cardiac repolarization (all anti-psychotics, several anti-depressants: nor/amytriptilline, fluoxetine, anti-emetics: domperidone (motilium) granisetron, ondansetron).

Exclusion criteria

Exclusion Criteria:

  1. Motoric abnormalities other than related to the mitochondrial disease interfering with the outcome parameters.
  2. CPEO patients with clinical signs and symptoms restricted to the eye only
  3. Heteroplasmy level as measured in urine \< 20%
  4. Poor nutritional state as judged by the investigator
  5. (BMI) not within 18.0-30.0 kg/m2 at screening.
  6. History of cancer
  7. Surgery or active illness of gastro-intestinal tract that might interfere with absorption.
  8. Participation in a trial of an product in the preceding 3 months prior to the first dose or during this trial.
  9. Positive drug, alcohol or cotinine test at screening and/or admission (Day 1 of the first dosing period).
  10. abnormal laboratory, recordings, cardiac echo (within 1 year prior to screening), vital signs or physical or mental findings at screening as judged by the Investigator.
  11. Clinically relevant abnormal ECG or cardiac functioning as judged by a cardiologist.
  12. ECG: > 450 ms, abnormal T-wave
  13. Symptomatic heart failure or signs of ischemic heart disease
  14. \<45%
  15. History or family history of congenital Long QT syndrome
  16. Increased or decreased potassium (local laboratory normal range)
  17. Inadequate use, pregnancy or breast feeding (females)
  18. Clinically significant presence or history of allergy as judged by the Investigator.
  19. History of or idiosyncrasy to any of the components of the investigational drug.
  20. Within 4 weeks prior to dosing, the use of:

    • (multi)vitamins, co-enzyme Q10, Vitamine E, riboflavin, and anti-oxidant supplements (and idebenone/EPI-743),
    • as well as any medication negatively influencing mitochondrial functioning (including but not limited to valproic acid, glitazones, statins, anti-virals, amiodarone, and NSAID's)
    • as well as any strong Cytochrome P450 inhibitors (all 'conazoles-anti-fungals', antivirals, grapefruit)
    • and strong Cytochrome P450 inducers (a.o. carbamazepine, phenobarbital, phenytoin, rifampicin, St Johns wort, pioglitazone, troglitazone)
    • as well as any medication known to affect cardiac repolarization (all anti-psychotics, several anti-depressants: nor/amitriptyline, fluoxetine, anti-emetics: domperidone (motilium) granisetron, ondansetron)
    • as well as any medication metabolized by Cytochrome P450 with a narrow therapeutical width. (for reference: drug interaction table of Indiana University http://medicine.iupui.edu/clinpharm/ddis/clinical-table/)
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Treatment A

    Oral administration of 100 mg KH176 twice daily

    Drug: KH176

  • Placebo comparator
    Treatment B

    Oral administration of matching placebo twice daily

    Drug: placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Movement disorders

    Rater assessed change from baseline of motoric abnormalities and movement characteristics

    Time frame: one month

Secondary outcomes

  1. NMDAS

    Change from baseline of the Newcastle Mitochondrial Disease Activity Score

    Time frame: one month

  2. Spirometric parameters (FVC,FEV1, PEF)

    Change from baseline in spirometric parameters

    Time frame: one month

  3. Spirometric parameters (MIP, MEP)

    Change from baseline in spirometric parameters

    Time frame: one month

  4. Sit to Stand Test (30 seconds)

    Change from baseline assessment of the maximum number of sit-standings in 30 seconds time

    Time frame: one month

  5. Handgrip Dynamometry

    Change from baseline assessment of the maximum grip strenght

    Time frame: one month

  6. 6-min chewing test

    Change from baseline assessment in rate of mastication

    Time frame: one month

  7. 6-min chewing test

    Change from baseline assessment of pain and tiredness (VAS) during a 6-min chewing test

    Time frame: one month

  8. 6-MWT

    Change from baseline assessment of the Distance during a 6-min Walk Test

    Time frame: one month

  9. RAND-SF36 score

    Change from baseline in the RAND-SF36

    Time frame: one month

  10. HAD and BDI

    Change from baseline in the Hospital Anxiety and Depression Scale (HAD), supplemented with a Beck Depression Index (BDI)

    Time frame: one month

  11. BDI

    Change from baseline in the Beck Depression Index (BDI)

    Time frame: one month

  12. CIS

    Change from baseline in the Checklist Individual Strength

    Time frame: one month

  13. TAP

    Change from baseline assessment of alertness and mental flexibility during a Test of Attentional Performance (TAP)

    Time frame: one month

  14. Goal Attainment Scale

    Assessment of pre-defined goal attainment during each treatment period

    Time frame: one month

  15. Registration of Motor Activity and Sleeping pattern

    During each treatment period a continuous registration of Motor Activity and Sleeping pattern by accelerometer, assessing sleep quality, quantity and overall motor activity

    Time frame: one month

  16. Vital Signs

    Change from Baseline assessment of vital signs (heart rate, blood pressure)

    Time frame: one month

  17. ECG

    Change from Baseline assessment of ECG-intervals

    Time frame: one month

  18. Clinical Laboratory

    Change from Baseline assessment of Clinical Laboratory parameters

    Time frame: one month

  19. Pharmacokinetics of KH176 and metabolites

    Attainment of steady state and total exposure (AUC) at steady state conditions

    Time frame: one month

  20. Pharmacokinetics of KH176 and metabolites

    Attainment of steady state and maximal concentrations (Cmax) at steady state conditions

    Time frame: one month

  21. Glutathione

    Change from baseline assessment of the ratio of oxidized/reduced glutathione in blood samples (GSH/GSSG)

    Time frame: one month

  22. Blood biomarker FGF21

    Change from baseline assessment of FGF21

    Time frame: one month

  23. Blood biomarker GDF15

    Change from baseline assessment of GDF15

    Time frame: one month

  24. Blood biomarker PRDX1

    Change from baseline assessment of PRDX1

    Time frame: one month

07

Study locations

1 site
  • Radboud University Medical Center
    Nijmegen, Netherlands
08

References and documents

Publications

  • Janssen MCH, Koene S, de Laat P, Hemelaar P, Pickkers P, Spaans E, Beukema R, Beyrath J, Groothuis J, Verhaak C, Smeitink J. The KHENERGY Study: Safety and Efficacy of KH176 in Mitochondrial m.3243A>G Spectrum Disorders. Clin Pharmacol Ther. 2019 Jan;105(1):101-111. doi: 10.1002/cpt.1197. Epub 2018 Sep 3. PubMed 30058726 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2016 to primary completion in Jul 2017, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2016
First posted
Sep 21, 2016
StartActual
Sep 2016
Primary completionActual
Jul 2017
CompletionActual
Jul 2017
Last update
Feb 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02909400
Lead sponsor
Khondrion BV
Responsible party
Sponsor
First posted
Sep 21, 2016
Start date
Sep 2016
Primary completion
Jul 2017
Completion
Jul 2017
Last update
Feb 23, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trolox

Start the discussion